The new price for its Covid-19 vaccine is lower than earlier deals – but arguably not by much.
This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.
Like many biotechs the group pushed on into phase III after a phase II failure; remarkably, the strategy has worked.
The liquid biopsy era is finally here.
Checkmate-743 brings success for Opdivo/Yervoy in mesothelioma, but should the combo be used in all-comers?
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
The purchase of Livongo is the richest healthcare deal this year, but questions about reimbursement, competition and profitability remain.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.
Encouraging immune responses and a competitive safety profile in a small trial seem to make Novavax’s vaccine a contender.
Fast tests for Covid-19 infections could be very useful – but only if they are accurate.
Suddenly 2020’s medtech M&A landscape looks very different.
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.
The latest Covid-19 vaccine award sees Glaxo and Sanofi score a $2.1bn windfall from the US government.
By signalling that its Covid-19 vaccine could cost just a few dollars Astra could seriously embarrass its competition.
Upcoming US approval verdicts include inclisiran, valrox and risdiplam, but toxicity issues could scupper filgotinib.
Poziotinib unexpectedly succeeds in a lung cancer niche, but competition from Takeda must be tracked closely.
There was a time when President Trump could mention drug pricing controls and move markets. Now, not so much.
The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.
The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.
A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.